General MedicationsORALStandard
MOVANTIK
NALOXEGOL OXALATE
Standard Dose
EQ 12.5MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview MOVANTIK is listed in Drugs@FDA under application 204760 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient NALOXEGOL OXALATE Form and strength TABLET;ORAL - EQ 12.5MG BASE Sponsor AVERITAS Submission history Latest submission status date: 2020-04-13 00:00:00.
Structured Monograph
Clinical summary
Approval overview MOVANTIK is listed in Drugs@FDA under application 204760 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient NALOXEGOL OXALATE Form and strength TABLET;ORAL - EQ 12.5MG BASE Sponsor AVERITAS Submission history Latest submission status date: 2020-04-13 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.